Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 264 publications
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
Journal: JAMA oncology
Published: June 04, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026
Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.
Journal: The Lancet. Respiratory medicine
Published: May 09, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2026
Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomes.
Journal: bioRxiv : the preprint server for biology
Published: February 23, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomes.
Journal: bioRxiv : the preprint server for biology
Published: February 23, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.
Journal: Science translational medicine
Published: February 04, 2026
Last Updated: 09/26/2026